KPTI Karyopharm Therapeutics Inc.

0  0%
Previous Close 5.94
Price To Book 2.98
Market Cap 361,534,803
Shares 60,864,445
Volume 15
Short Ratio
Av. Daily Volume 937,258

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due in 2020.
Selinexor - SEAL
Dedifferentiated liposarcoma
PDUFA date under priority review extended by three months to July 6, 2019. Advisory Committee February 26, 2019 voted 8-5 recommending that approval decision is held off until after the release of data from BOSTON trial, late-2019/2020.
Quadruple Refractory Multiple Myeloma
Phase 3 data due end of 2019 or into 2020.
Selinexor - BOSTON
Multiple myeloma
NDA filing due 1H 2020.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 enrolment to be completed 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data reported at ASCO-GU 2019.
Solid tumors
Phase 1/2 updated tolerability data due 2019.
Non-Hodgkin Lymphoma

Latest News

  1.  Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
  2. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. Karyopharm to Participate in Upcoming Investor Conferences
  4. Edited Transcript of KPTI earnings conference call or presentation 9-May-19 12:30pm GMT
  5. Karyopharm Therapeutics Inc. (KTPI) Q1 2019 Earnings Call Transcript
  6. Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
  7. Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
  8. Here’s What Hedge Funds Think About Karyopharm Therapeutics Inc (KPTI)
  9. Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
  10. Karyopharm Therapeutics: 1Q Earnings Snapshot
  11. Earnings Preview: Karyopharm Therapeutics (KPTI) Q1 Earnings Expected to Decline
  12. Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019
  13. Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Are Analysts Bullish?
  14. Here's Why Karyopharm Therapeutics Climbed Today
  15. Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
  16. Why Karyopharm Therapeutics Stock Is Soaring Today
  17. The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA